Syndax Pharmaceuticals Reports Strong Q4 & Full Year 2025 Revenue Growth, Advances Pipeline, and Nears Profitability
Summary
Syndax Pharmaceuticals reported robust revenue growth for Q4 and full year 2025, driven by strong sales of Revuforj and Niktimvo, while also advancing its clinical pipeline and projecting a path to profitability.
Key Events
-
Strong Revenue Growth
Total revenue for Q4 2025 reached $68.7 million, with Revuforj net revenue increasing 38% quarter-over-quarter to $44.2 million and Niktimvo net revenue growing 22% to $56.0 million. Full year 2025 total revenue was $172.4 million.
-
Reduced Net Loss
The net loss attributable to common stockholders decreased to $68.0 million in Q4 2025 from $94.2 million in Q4 2024, and to $285.4 million for the full year 2025 from $318.8 million in 2024.
-
Solid Financial Position & Path to Profitability
Syndax ended 2025 with $394.1 million in cash, cash equivalents, and short-term investments. The company expects its operating expense base to remain stable and anticipates reaching profitability with current resources and projected revenues.
-
Key Pipeline Advancements
Enrollment was completed in the Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF), with topline data expected in Q4 2026. The company also initiated REVEAL-ND, a Phase 3 trial for revumenib in newly diagnosed NPM1m AML.
Analysis
Syndax Pharmaceuticals delivered robust financial results for the fourth quarter and full year 2025, showcasing significant commercial momentum for its key products, Revuforj and Niktimvo. Revuforj net revenue surged 38% quarter-over-quarter to $44.2 million in Q4 2025, while Niktimvo net revenue increased 22% to $56.0 million. The company also reported a reduced net loss for both the quarter and the full year, indicating improving financial health. With $394.1 million in cash and equivalents, Syndax projects a stable operating expense base and expects to reach profitability with its current financial resources and anticipated product revenue. Additionally, the company achieved key pipeline milestones, including completing enrollment in the Phase 2 IPF trial for axatilimab and initiating a pivotal Phase 3 trial for revumenib in newly diagnosed AML, reinforcing its growth trajectory.
At the time of this filing, SNDX was trading at $20.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $8.58 to $22.73. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.